FIELD: biotechnology.
SUBSTANCE: group of inventions including a lipid nanoparticle for the treatment of liver tumor diseases in a patient, a pharmaceutical composition for the treatment of a liver tumor disease in a patient, and the use of a pharmaceutical composition for the production of a drug for the treatment of a liver tumor disease in a patient are described.
EFFECT: invention expands the arsenal of agents for the treatment of tumor diseases of the liver in a patient.
7 cl, 3 dwg, 4 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR FORMING IMMUNE SURVEILLANCE SYSTEM FOR TUMOUR CELLS IN MAMMAL BODY | 2024 |
|
RU2828654C1 |
| BCMA-SPECIFIC CHIMERIC ANTIGEN RECEPTORS CONTAINING IL-6 SIGNALLING BLOCKER | 2023 |
|
RU2828294C1 |
| METHOD OF PRODUCING MOUSE MODEL FOR STUDYING DUCHENNE MUSCULAR DYSTROPHY AND VERSIONS OF ITS THERAPY | 2023 |
|
RU2815936C1 |
| BISPECIFIC ANTIBODIES AND THEIR APPLICATIONS | 2022 |
|
RU2821577C2 |
| COMPOSITIONS AND METHODS FOR INHIBITION OF PROTEOLYTIC PATH OF ARGININE/N-DEGRON | 2020 |
|
RU2787841C2 |
| MONOCLONAL ANTIBODIES AGAINST THE RECEPTOR-BINDING DOMAIN OF SARS-COV-2 SPIKE PROTEIN AND THEIR ANTIGEN-BINDING FRAGMENTS ENCODING THEIR NUCLEIC ACIDS, AS WELL AS METHODS OF THEIR USE | 2021 |
|
RU2800649C2 |
| METHOD FOR GENOTYPING NEISSERIA GONORRHOEAE ISOLATES ON BIOLOGICAL MICROCHIP | 2023 |
|
RU2816767C1 |
| DOUBLE-STRANDED RNA CAPABLE OF REDUCING EXPRESSION OF MUTANT ALLELE C.607G>A OF HUMAN GNAO1 GENE | 2022 |
|
RU2816137C1 |
| SYSTEM OF TARGETED SPLICING CHANGES IN MARK2 GENE | 2023 |
|
RU2810907C1 |
| MUS MUSCULUS 5B9 HYBRID CULTIVATED ANIMAL CELLS- A PRODUCER OF MOUSE MONOCLONAL ANTIBODY 5B9, MONOCLONAL MOUSE ANTIBODY 5B9 AND RECOMBINANT CHIMERIC (MOUSE-HUMAN) ANTIBODY XI5B9, NEUTRALIZING RICIN RICINUS COMMUNIS | 2022 |
|
RU2802436C1 |
